SEC Form 4 · accession 0001209191-19-006612
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Shak
Officer — Chief Scientific Officer
Period of report
Jan 30, 2019
Accepted (ET)
Feb 1, 2019 · 7:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 30, 2019 | M | 25,000 | $29.34 | A | 364,671 | I | Held by the Shak Family Trust |
| Common StockF2,F3,F4,F1 | Jan 30, 2019 | S | 3,101 | $72.0054 | D | 361,570 | I | Held by the Shak Family Trust |
| Common StockF2,F3,F5,F1 | Jan 30, 2019 | S | 10,215 | $73.1157 | D | 351,355 | I | Held by the Shak Family Trust |
| Common StockF2,F3,F6,F1 | Jan 30, 2019 | S | 11,418 | $74.1995 | D | 339,937 | I | Held by the Shak Family Trust |
| Common StockF2,F3,F7,F1 | Jan 30, 2019 | S | 266 | $74.6374 | D | 339,671 | I | Held by the Shak Family Trust |
| Common StockF1 | Jan 31, 2019 | M | 25,000 | $29.34 | A | 364,671 | I | Held by the Shak Family Trust |
| Common StockF2,F3,F8,F1 | Jan 31, 2019 | S | 1,808 | $73.5797 | D | 362,863 | I | Held by the Shak Family Trust |
| Common StockF2,F3,F9,F1 | Jan 31, 2019 | S | 5,364 | $74.2846 | D | 357,499 | I | Held by the Shak Family Trust |
| Common StockF2,F3,F10,F1 | Jan 31, 2019 | S | 17,673 | $75.3299 | D | 339,826 | I | Held by the Shak Family Trust |
| Common StockF2,F3,F11,F1 | Jan 31, 2019 | S | 155 | $75.9387 | D | 339,671 | I | Held by the Shak Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F12 | $29.34 | Jan 30, 2019 | M | 25,000 | D | — | Feb 5, 2022 | Common Stock | 25,000 | 25,000 | D |
| Employee Stock Option (right to buy)F12 | $29.34 | Jan 31, 2019 | M | 25,000 | D | — | Feb 5, 2022 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1Includes an aggregate of 16,250 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F10Represents weighted average sale price. Actual sale prices ranged from $74.88 to $75.87.
- F11Represents weighted average sale price. Actual sale prices ranged from $75.90 to $75.96.
- F12The option became exercisable as to 25% of the shares on February 5, 2013, and became exercisable as to 1/48th of the shares each full month thereafter.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 30, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $71.47 to $72.45.
- F5Represents weighted average sale price. Actual sale prices ranged from $72.60 to $72.585.
- F6Represents weighted average sale price. Actual sale prices ranged from $73.60 to $74.53.
- F7Represents weighted average sale price. Actual sale prices ranged from $74.63 to $74.66.
- F8Represents weighted average sale price. Actual sale prices ranged from $72.81 to $73.80.
- F9Represents weighted average sale price. Actual sale prices ranged from $73.82 to $74.79.